Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience
Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Michael Byrne(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Brian G. Engelhardt(Vanderbilt University Medical Center), Nasima Mehraban(Vanderbilt University Medical Center), Brittney Baer(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Nancy Long(Vanderbilt University Medical Center)
Cited by 25
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782